Sometimes, one just has to wonder how the FDA prioritizes things. In an otherwise boring year in which very few NDAs will be introduced, I guess we have our answer: time to get serious about tighter regulations on the patterns of prescription narcotic writing in this country. The organization is just now paying attention to this issue? Apparently so.

Yesterday, the FDA announced it was stepping up efforts to reduce unsafe use of some 24 narcotics products — methadone pills, fentanyl patches and extended-release pills containing morphine, oxymorphone and oxycodone — all agents and formulations with a well known propensity for drug dependence and street trafficking. Alrighty, then. | LINK

Related Posts Within Doctor Pundit:

1. Pharma Using Physician Social Networks as Potential Marketing Opportunity Has the need for attention and online social contacts been...
2. Obama’s Commitment to Healthcare Reform Acknowledges Potential Savings from Specialized Pharmaceutical Research Out of the distribution of the hundreds of billions President...
3. FDA Rejects Plan to Increase Controls on Opioid Prescribing Besides making news on the antidiabetic treatment front recently with...
4. Court: E-Cigarettes Should Be Treated Like Tobacco A new way for some to curb the addiction to...
5. FDA Criticized for Lack of Controls over Increasing Prescription Narcotic Abuse The rise in prescription drug abuse in this country has...